The Journal of Long-Term Effects of Medical Implants, March 2021 The primary objective of this study was to determine the effect of single versus multiple rounds of intra-articular hyaluronic acid (IA-HA) in delaying the need for total knee arthroplasty (TKA) in patients with knee OA, and if additional benefits were seen when used in conjunction with other multimodal treatment options. Methods … Read More
JAMA Network Open, March 2021 BHI co-authored a study in the JAMA Network Open that found almost 24% of privately insured working-age individuals used telehealth for outpatient care in the early phase of the pandemic compared to just 0.3% during the same time in 2019.
Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, March 2021 The primary objective of this study was to examine the relationship between intra-articular hyaluronic acid (IA-HA) treatment and delaying TKA in patients with KOA compared to patients not receiving IA-HA, as well as to identify differences in KOA-related costs incurred among patients who received or did not receive IA-HA.
Journal of Orthopaedic Surgery and Research, August 2020 Limiting treatment to those recommended by the American Academy of Orthopaedic Surgeon Clinical Practice Guidelines has been suggested to decrease costs by 45% in the year prior to total knee arthroplasty, but this only focuses on expenditures leading up to, but not including, the surgery and not the entire episode of care. BHI’s … Read More
The American Journal of Managed Care, February 2020 A budget impact analysis was conducted from a U.S. commercial payer perspective over a 1-year time horizon with patients who received the implant or revision ESS. Primary outcomes of interest were annual total and per-member per-month (PMPM) direct health care costs. Costs were estimated using a decision analysis model, assuming 50% implant … Read More
Journal of Vascular Surgery: Venous and Lymphatic Disorders, September 2019 To determine the proportion of LE patients with various LE-associated comorbidities as well as the rate of associated treatment, deidentified Health Insurance Portability and Accountability Act-compliant commercial administrative claims from the Blue Health Intelligence® (BHI®) research database (165 million Blue Cross Blue Shield members) were queried. We analyzed a BHI … Read More
Journal of Managed Care & Specialty Pharmacy, August 2019 A budget impact analysis was conducted from a U.S. commercial payer perspective over a 1-year time horizon with patients who received the implant or revision ESS. Primary outcomes of interest were annual total and per-member per-month (PMPM) direct health care costs. Costs were estimated using a decision analysis model, assuming 50% … Read More
Journal of the American Society of Plastic Surgeons, October 2018 Using the Blue Health Intelligence® database from 2009 to 2013, patients were identified who underwent tissue expander (i.e., implant) or free-flap breast reconstruction. The implant-to-flap ratio and physician payments were assessed using quadratic modeling. Matched bootstrapped samples from the early and late periods generated probability distributions, approximating the odds of … Read More
Journal of Medical Economics, July 2018 Budget impact was calculated over 2 years for a hypothetical US payer with 10-million commercial members. Model inputs were derived from published sources and from a case-matched analysis of Blue Health Intelligence® (BHI®) claims data for the years 2012-2016.
Journal of Vascular Surgery, June 2018 This was a longitudinal matched case-control analysis of deidentified private insurance claims. The study used administrative claims data from Blue Health Intelligence® for the complete years 2012 through 2016. Patients were continuously enrolled for at least 18 months, diagnosed with phlebolymphedema, and received at least one claim for CONS either alone or in addition … Read More
- Page 1 of 2